BLINCYTO® Patient Website — Learn About BLINCYTO®. Visit For Full Safety, Prescribing...
Connect With A Rep — Review BLINCYTO® Full Safety and Dosing Information. Download Helpful HCP Resources. Physicians: Get Product & Dosing Info. Explore The Latest Clinical Study Data & Learn More. FDA-Approved.
Blinatumomab
Używka
Blinatumomab, sprzedawany pod marką Blincyto i znany nieformalnie jako blina, to lek biofarmaceutyczny stosowany w leczeniu drugiego rzutu w leczeniu ostrej białaczki limfoblastycznej z ujemnym chromosomem Filadelfia, nawrotowej lub opornej na... Wikipedia (angielski)
25 sty 2023 · Blinatumomab extends life for people with acute lymphoblastic leukemia who are in remission, even those who are MRD-negative, a trial has ...
Blinatumomab, sold under the brand name Blincyto, and known informally as blina, is a biopharmaceutical medication used as a second-line treatment for ...
Blinatumomab is a type of targeted cancer drug called immunotherapy. It might also be called a monoclonal antibody. It works by targeting a certain protein on ...
BLINCYTO® is a prescription medicine used to treat adults and children with: B-cell precursor acute lymphoblastic leukemia (ALL) in remission when only a ...
1 kwi 2021 · The immunotherapy drug blinatumomab (Blincyto) is more effective than chemotherapy in treating B-cell acute lymphoblastic leukemia (B-ALL) ...
4 sty 2023 · In a Phase 2 trial in patients with MRD+ B-cell ALL, 78% of patients receiving blinatumomab achieved a complete MRD response, which was ...
Blinatumomab is thought to activate T cells in the presence of B target cells, which induces secretion of cytokines and chemokines. This massive influx could ...
13 gru 2022 · Blinatumomab is a bispecific antibody that works by bringing a patient's T cells into close proximity to leukemia cells so that the immune ...
3 paź 2016 · Blinatumomab is a bispecific T-cell engager (BiTE) antibody construct that directs CD3-positive effector memory T cells to CD19-positive target ...
